Project description:It’s unknown what, how, and why lipid metabolites involve in cancer prognosis. This work implementing multi-omics measurement in hepatocellular carcinoma (HCC) patient cohort to associate tumoral lipidome, transcriptome, and serological metabolome to disease prognosis. Data indicating that dietary related ether-lipids, e.g., PC O- and PE O-, promote cell mobility and poor prognosis through TRPV2-related cytoskeletal rearrangement. In addition, downregulation of Peroxisome Proliferator-Activated Receptorα (PPARα) and consequential lipophagic deficit increase ether-lipids in cancer cells. Unfortunately, pathological coupling of Very Low-Density Lipoprotein Receptor (VLDLR) overexpression in HCC patients, concordantly deteriorates ether-lipid accumulation and facilitate HCC prognosis via VLDL entrance, the diet direct responding lipoprotein. Knocking out hepatic VLDLR reduce HCC burden in human etiology-related spontaneous HCC mouse model, which demonstrated the pathological causality in HCC. At last, administration of VLDL-Mimicking Nanoparticle encapsulating Lenvatinib, or fenofibrate (PPAR αagonist) could effectively diminished tumor anarchy.

2025-08-29 | GSE242315 | GEO

Asan Medical Center Data Access Commitee

Project description:Data Access Committee EGAC00001002864

| EGAC00001002864 | EGA

Asan Medical Center Data Access Commitee

Project description:Data Access Committee EGAC00001002991

| EGAC00001002991 | EGA

Joint Addiction, Aging, and Mental Health Data Access Committee General Research Use Datasets (GSR restricted) Collection

Project description:Joint Addiction, Aging, and Mental Health Data Access Committee General Research Use Datasets (GSR restricted) Collection

| PRJNA1018662 | ENA